CRT-D Benefits Are Prolonged in Heart Failure

Long-term follow-up data continue to show improved survival using ICD with resynchronization.

In the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT; NCT00251251), use of a cardiac-resynchronization therapy defibrillator (CRT-D) significantly reduced all-cause death or hospitalization for heart failure at 5 years' follow-up compared with a standard implantable cardioverter-defibrillator (ICD) in 1798 patients with left ventricular ejection fraction (LVEF) ≤30%, QRS duration ≥120 msec, and NYAH class II or III heart failure. Now, investigators report extended follow-up results in a subset of 1050 patients.

Participants were not excluded for having right bundle-branch block, nonspecific interventricular conduction delays, right ventricular pacing, or atrial fibrillation. In the initial study, average follow-up…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

CRT-D Benefits Are Prolonged in Heart Failure

Topics

Reviewing Author